Last reviewed · How we verify

Placebo + valacyclovir — Competitive Intelligence Brief

Placebo + valacyclovir (Placebo + valacyclovir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral nucleoside analog. Area: Oncology.

phase 3 Antiviral nucleoside analog Herpes simplex virus DNA polymerase Oncology Biologic Live · refreshed every 30 min

Target snapshot

Placebo + valacyclovir (Placebo + valacyclovir) — Candel Therapeutics, Inc.. Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo + valacyclovir TARGET Placebo + valacyclovir Candel Therapeutics, Inc. phase 3 Antiviral nucleoside analog Herpes simplex virus DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral nucleoside analog class)

  1. Candel Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo + valacyclovir — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-valacyclovir. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: